{"result": "(\"entity\"<|>HEMBREE WC<|>PERSON<|>Hembree WC is an author of the clinical practice guideline on endocrine treatment for gender-dysphoric individuals.)\n##\n(\"entity\"<|>COHEN-KETTENIS PT<|>PERSON<|>Cohen-Kettenis PT is an author of the clinical practice guideline on endocrine treatment for gender-dysphoric individuals.)\n##\n(\"entity\"<|>GOOREN L<|>PERSON<|>Gooren L is an author of the clinical practice guideline on endocrine treatment for gender-dysphoric individuals.)\n##\n(\"entity\"<|>HANNEMA SE<|>PERSON<|>Hannema SE is an author of the clinical practice guideline on endocrine treatment for gender-dysphoric individuals.)\n##\n(\"entity\"<|>MEYER WJ<|>PERSON<|>Meyer WJ is an author of the clinical practice guideline on endocrine treatment for gender-dysphoric individuals.)\n##\n(\"entity\"<|>MURAD MH<|>PERSON<|>Murad MH is an author of the clinical practice guideline on endocrine treatment for gender-dysphoric individuals.)\n##\n(\"entity\"<|>ENDOCRINE SOCIETY<|>ORGANIZATION<|>The Endocrine Society is a professional organization that provides clinical practice guidelines for endocrine treatments.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a medical information provider that offers clinical guidelines and references for healthcare professionals.)\n##\n(\"entity\"<|>CRYPTORCHIDISM<|>EVENT<|>Cryptorchidism refers to the condition of undescended testicles, which is the focus of the clinical practice guidelines discussed.)\n##\n(\"relationship\"<|>HEMBREE WC<|>ENDOCRINE SOCIETY<|>Hembree WC is an author of the clinical practice guideline published by the Endocrine Society<|>8)\n##\n(\"relationship\"<|>COHEN-KETTENIS PT<|>ENDOCRINE SOCIETY<|>Cohen-Kettenis PT is an author of the clinical practice guideline published by the Endocrine Society<|>8)\n##\n(\"relationship\"<|>GOOREN L<|>ENDOCRINE SOCIETY<|>Gooren L is an author of the clinical practice guideline published by the Endocrine Society<|>8)\n##\n(\"relationship\"<|>HANNEMA SE<|>ENDOCRINE SOCIETY<|>Hannema SE is an author of the clinical practice guideline published by the Endocrine Society<|>8)\n##\n(\"relationship\"<|>MEYER WJ<|>ENDOCRINE SOCIETY<|>Meyer WJ is an author of the clinical practice guideline published by the Endocrine Society<|>8)\n##\n(\"relationship\"<|>MURAD MH<|>ENDOCRINE SOCIETY<|>Murad MH is an author of the clinical practice guideline published by the Endocrine Society<|>8)\n##\n(\"relationship\"<|>CRYPTORCHIDISM<|>ENDOCRINE SOCIETY<|>The Endocrine Society provides guidelines for the treatment of cryptorchidism<|>7)\n##\n(\"relationship\"<|>UPTODATE INC<|>ENDOCRINE SOCIETY<|>UpToDate Inc. references the clinical practice guidelines published by the Endocrine Society<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ende conseguir el descenso del testículo mediante un aumento\n               micos, por su efecto sobre el primer paso hepático, en relación con la dosis utilizada. En                                            de testosterona a nivel intratesticular con la hCG (gonadotrofina coriónica humana) y los\n               los pacientes de mayor edad, que están más expuestos a mayor riesgo de enfermedad                                                     aGnRH (análogos de GnRH). La asociación de hCG con HMG (gonadotrofina menopáusica\n               tromboembólica, debe restringirse el uso de estrógenos orales. Las preparaciones trans-                                               humana con acción FSH y LH) o el tratamiento con GnRH se ha defendido con la intención\n               dérmicas y el cipionato de estradiol o valerato inyectables pueden conferir una ventaja                                               de mejorar la respuesta espermática.\n               en las mujeres transexuales mayores que pueden tener un mayor riesgo de enfermedad\n               tromboembólica.                                                                                                                       Ninguno     de   estos   tratamientos      médicos      ha  demostrado       definitivamente       su  eficacia   en\n               Es conveniente la monitorización de los niveles séricos de estradiol en pacientes que usen                                            cuanto a descenso testicular, no superando el 20%, con otro 20% de reascensos en quienes\n               estradiol oral, transdérmico e intramuscular, aunque no sea útil si usan estrógenos conju-                                            lo consiguen. La respuesta al tratamiento médico de las criptorquidias se relaciona con\n               gados o sintéticos.                                                                                                                   la localización; responden mejor los más distales, y se puede interpretar como respuesta\n                                                                                                                                                     el descenso de un testículo en ascensor más que una verdadera criptorquidia. El tratamien-\n               El estradiol sérico y la testosterona sérica deben mantenerse en el nivel para mujeres pre-                                           to médico se plantea para testículos criptorquídicos que se puedan bajar en la exploración\n               menopáusicas (100 a 200 pg/ml y 50 ng/dl, respectivamente).                                                                           hasta la parte alta del escroto, pero no puedan descender completamente, o que se en-\n               Referencias:                                                                                                                          cuentran en localización supraescrotal. Estos tratamientos son bien tolerados, aunque se\n               • Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine Treatment of Gender-Dysphoric/Gen-        han descrito signos de virilización reversibles (aumento del pene y/o del vello pubiano, o\n                 der-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab [Internet]. 2017;102(11):3869-  hiperpigmentación escrotal).\n                 903. https://doi.org/10.1210/jc.2017-01658\n                                                                                                                                                     También se ha planteado como adyuvante antes o después del tratamiento quirúrgico, para\n                                                                                                                                                     mejorar la fertilidad, por mejorar las características del semen, pero los resultados son\n     6.7 Otros                                                                                                                                       también contradictorios.\n                                                                                                                                                     El tratamiento quirúrgico es el tratamiento de elección para la mayoría de las criptor-\n                                                                                                                                                     quidias. Debe recomendarse tan pronto como sea posible en testículos palpables, tras los\n        22     Con respecto al tratamiento médico de la criptorquidia, señale la respuesta cierta:                                                   4 meses de edad y antes de los 2 años (preferentemente antes del año) para mejorar en lo\n               A. El tratamiento hormonal está asociado a altas tasas de respuesta (>80%) comparado con                                              posible su crecimiento y capacidad reproductora, que puede quedar comprometida en estos\n                   placebo.                                                                                                                          pacientes. El tratamiento antes de la pubertad reduce además el riesgo de cáncer y torsión\n               B. El tratamiento con análogos de GnRH tiene mayor tasa de respuestas que el tratamiento                                              testicular. Es un tratamiento eficaz en más del 90% de casos, y las complicaciones son poco\n                                                                                                                                                     frecuentes en manos expertas (atrofia, reascenso, hernia inguinal, infección o sangrado).\n                   con hCG.\n               C. La localización inicial de los testes no influye en las tasas de respuesta.                                                        La orquidopexia es la técnica de elección y consiste en la colocación quirúrgica del testí-\n               D.  Todas son falsas.                                                                                                                 culo en el escroto por vía inguinal o escrotal, si está localizado el testículo y lo permite el\n                                                                                                                                                     tamaño y vascularización.\n                                                                                                                                                     Referencias:\n               COMENTARIO                                                                                                                            • Cooper CS, Docimo SG. Undescended testes (cryptorchidism) in children: Management. Drutz JE et al, eds. UpToDate. Waltham,\n                                                                                                                                                       MA: UpToDate Inc. https://www.uptodate.com (Apr 02 2019.)\n               Se entiende por criptorquidia un testículo oc\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}